Jason A. Holt
GlaxoSmithKline
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jason A. Holt.
Aging Cell | 2016
Aaron C. Hinken; Janine Powers; Guizhen Luo; Jason A. Holt; Andrew N. Billin; Alan Russell
Recent high‐profile studies report GDF11 to be a key circulating ‘anti‐aging’ factor. However, a screen of extracellular proteins attempting to identify factors with ‘anti‐aging’ phenotypes in aged murine skeletal muscle satellite cells did not identify GDF11 activity. We have been unable to confirm the reported activity of GDF11, similar to other laboratories offering conflicting data and describe our attempts to do so in this short take.
Journal of Medicinal Chemistry | 2010
Christopher M. Yates; Peter J. Brown; Eugene L. Stewart; Christopher Patten; Robert J. H. Austin; Jason A. Holt; Jodi M. Maglich; Davina C. Angell; Rosemary Sasse; Simon Taylor; Iain Uings; Ryan P. Trump
Glucocorticoid receptor (GR) agonists have been used for more than half a century as the most effective treatment of acute and chronic inflammatory conditions despite serious side effects that accompany their extended use that include glucose intolerance, muscle wasting, skin thinning, and osteoporosis. As a starting point for the identification of GR ligands with an improved therapeutic index, we wished to discover selective nonsteroidal GR agonists and antagonists with simplified structure compared to known GR ligands to serve as starting points for the optimization of dissociated GR modulators. To do so, we selected multiple chemical series by structure guided docking studies and evaluated GR agonist activity. From these efforts we identified 5-arylindazole compounds that showed moderate binding to the glucocorticoid receptor (GR) with clear opportunities for further development. Structure guided optimization was used to design arrays that led to potent GR agonists and antagonists. Several in vitro and in vivo experiments were utilized to demonstrate that GR agonist 23a (GSK9027) had a profile similar to that of a classical steroidal GR agonist.
British Journal of Pharmacology | 2013
Iain Uings; Deborah Needham; Joyce Lesley Matthews; Michael V. Haase; R Austin; Davina C. Angell; Karen Leavens; Jason A. Holt; Keith Biggadike; Stuart N. Farrow
Glucocorticoids are highly effective therapies for a range of inflammatory diseases. Advances in the understanding of the diverse molecular mechanisms underpinning glucocorticoid action suggest that anti‐inflammatory molecules with reduced side effect liabilities can be discovered. Here we set out to explore whether modification of the 17α position of the steroid nucleus could generate molecules with a unique pharmacological profile and to determine whether such molecules would retain anti‐inflammatory activity.
ACS Chemical Biology | 2016
Andrew N. Billin; Marcus Bantscheff; Gerard Drewes; Sonja Ghidelli-Disse; Jason A. Holt; Henning F. Kramer; Alan J. McDougal; Terry L. Smalley; Carrow I. Wells; William J. Zuercher; Brad R. Henke
Skeletal muscle progenitor stem cells (referred to as satellite cells) represent the primary pool of stem cells in adult skeletal muscle responsible for the generation of new skeletal muscle in response to injury. Satellite cells derived from aged muscle display a significant reduction in regenerative capacity to form functional muscle. This decrease in functional recovery has been attributed to a decrease in proliferative capacity of satellite cells. Hence, agents that enhance the proliferative abilities of satellite cells may hold promise as therapies for a variety of pathological settings, including repair of injured muscle and age- or disease-associated muscle wasting. Through phenotypic screening of isolated murine satellite cells, we identified a series of 2,4-diaminopyrimidines (e.g., 2) that increased satellite cell proliferation. Importantly, compound 2 was effective in accelerating repair of damaged skeletal muscle in an in vivo mouse model of skeletal muscle injury. While these compounds were originally prepared as c-Jun N-terminal kinase 1 (JNK-1) inhibitors, structure-activity analyses indicated JNK-1 inhibition does not correlate with satellite cell activity. Screening against a broad panel of kinases did not result in identification of an obvious molecular target, so we conducted cell-based proteomics experiments in an attempt to identify the molecular target(s) responsible for the potentiation of the satellite cell proliferation. These data provide the foundation for future efforts to design improved small molecules as potential therapeutics for muscle repair and regeneration.
Genes & Development | 2003
Jason A. Holt; Guizhen Luo; Andrew N. Billin; John E. Bisi; Y. Yvette McNeill; Karen F. Kozarsky; Mary H. Donahee; Da Yuan Wang; Traci Ann Mansfield; Steven A. Kliewer; Bryan Goodwin; Stacey A. Jones
European Respiratory Journal | 2013
Stuart N. Farrow; Iain Uings; Michael V. Haase; Davina C. Angell; Karen Leavens; Jason A. Holt; Joyce Lesley Matthews; Keith Biggadike; Deborah Needham
British Journal of Pharmacology | 2013
Iain Uings; Deborah Needham; Joyce Lesley Matthews; Michael V. Haase; R Austin; Davina C. Angell; Karen Leavens; Jason A. Holt; Keith Biggadike; Stuart N. Farrow
Archive | 2010
David M. Lonard; Rakesh Kumar; Bert W. O'malley; Heng-Yu Fan; JoAnne S. Richards; William A. Alaynick; Stephanie A. Wilson; William G. Benson; Liming Pei; Michael A. Downes; Ruth T. Yu; Johan W. Jonker; Jason A. Holt; Deepak K. Rajpal; Hao Li; Joan Stuart; Ruth McPherson; Katja S. Remlinger; Ching-Yi Chang; Donald P. McDonnell; Ronald M. Evans; Andrew N. Billin
Endocrine Reviews | 2009
William A. Alaynick; James M. Way; Stephanie A. Wilson; William G. Benson; Liming Pei; Michael Downes; Ruth T. Yu; Johan W. Jonker; Jason A. Holt; Deepak K. Rajpal; Hao Li; Joan Stuart; Ruth McPherson; Katja S. Remlinger; Ching Yi-Chang; Donald P. McDonnell; Ronald M. Evans; Andrew N. Billin
Archive | 2002
Jason A. Holt; Jodi M. Maglich; John T. Moore